Plain-English translation of NCT07213765 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing whether adding , a newer antibiotic, to the standard treatment plan can help people with avium pulmonary disease recover faster and with a shorter course of treatment. Some participants will take the new medication plus standard antibiotics for 6 months, while others will take standard antibiotics alone for 12 months. Researchers want to see if the newer medication helps reduce the bacteria and lung damage more effectively.
Avium pulmonary disease is a serious lung infection that typically requires a very long course of antibiotics—often a year or more—which can be hard on patients and their bodies. This trial is exploring whether this medication can shorten that treatment time and improve patients' quality of life.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups: either taking the new medication daily plus standard antibiotics three times a week for 6 months, or taking standard antibiotics alone three times a week for 12 months. You will visit the clinic once a month for checkups, blood tests, and imaging to monitor how well the treatment is working and watch for any side effects. The study tracks how much bacteria is in your lungs, how your lung damage looks on scans, and how you feel overall.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China